Interaction of @entity13586 and @entity12698 with XXXX .

@entity1 @entity13586 @entity12698 @entity137 @entity4 @entity65722 @entity1443 @entity3840 @entity1229
The interaction of @entity12698 and @entity13586 with @entity1229 was studied. @entity1 stable on @entity1229 therapy and concurrently taking a @entity3840 ( @entity3840 ) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, @entity65722 , or @entity1443 ) randomly received @entity12698 200 mg/day or @entity13586 25 mg/day for three weeks. After a one-week washout period, the @entity1 were crossed over to treatment with the opposite @entity3840 inhibitor for three more weeks. The International Normalized Ratio (INR) was measured at baseline and at weeks 1, 2, and 3 of therapy with each @entity3840 inhibitor by testing blood samples obtained by finger stick. Data for 16 @entity1 were analyzed. The INR increased by 13%, 6%, and 5% on average in @entity1 taking @entity12698 at weeks 1, 2, and 3, respectively, and by 5%, 9%, and 5% in @entity1 taking @entity13586 . Changes in the INR were statistically significant at week 1 for @entity12698 and at week 2 for @entity13586 . Of the 12 subjects who had a clinically significant > or = 15% change in the INR while receiving either @entity3840 inhibitor, 4 showed this change for both agents. @entity137 were similar for each @entity3840 inhibitor, but the rate of @entity4 requiring medical intervention was higher in the @entity13586 group. Significant increases in the INR were observed in @entity1 who were stable on @entity1229 therapy after the addition of therapy with @entity13586 or @entity12698 .
